62 related articles for article (PubMed ID: 24297112)
21. The Natural Product Oridonin as an Anticancer Agent: Current Achievements and Problems.
Hu X; Huang S; Ye S; Jiang J
Curr Pharm Biotechnol; 2024; 25(6):655-664. PubMed ID: 37605407
[TBL] [Abstract][Full Text] [Related]
22. Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.
Triantafillidis JK; Triantafyllidi E; Sideris M; Pittaras T; Papalois AE
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276978
[TBL] [Abstract][Full Text] [Related]
23. Oridonin enhances the anti-tumor activity of gemcitabine towards pancreatic cancer by stimulating Bax- and Smac-dependent apoptosis.
Liu DL; Bu HQ; Wang WL; Luo H; Cheng BN
Transl Cancer Res; 2020 Jul; 9(7):4148-4161. PubMed ID: 35117784
[TBL] [Abstract][Full Text] [Related]
24. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling.
Zhao X; Zhang Q; Wang Y; Li S; Yu X; Wang B; Wang X
Ann Transl Med; 2021 Jul; 9(13):1084. PubMed ID: 34422996
[TBL] [Abstract][Full Text] [Related]
25. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells.
Qin AC; Jin H; Song Y; Gao Y; Chen YF; Zhou LN; Wang SS; Lu XS
Cell Death Dis; 2020 Sep; 11(9):805. PubMed ID: 32978368
[TBL] [Abstract][Full Text] [Related]
26. Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway.
Wang Y; Zhu Z
Arch Med Sci; 2019 Jul; 15(4):1017-1027. PubMed ID: 31360196
[TBL] [Abstract][Full Text] [Related]
27. Oridonin induces growth inhibition and apoptosis in human gastric carcinoma cells by enhancement of p53 expression and function.
Bi E; Liu D; Li Y; Mao X; Wang A; Wang J
Braz J Med Biol Res; 2018 Nov; 51(12):e7599. PubMed ID: 30462771
[TBL] [Abstract][Full Text] [Related]
28. Oridonin inhibits growth and induces apoptosis of human neurocytoma cells via the Wnt/β-catenin pathway.
Liang J; Wang W; Wei L; Gao S; Wang Y
Oncol Lett; 2018 Sep; 16(3):3333-3340. PubMed ID: 30127932
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells
Zhu J; Ji Y; Yu Y; Jin Y; Zhang X; Zhou J; Chen Y
Oncol Lett; 2018 Jun; 15(6):8761-8769. PubMed ID: 29805615
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the JNK/MAPK signaling pathway by myogenesis-associated miRNAs is required for skeletal muscle development.
Xie SJ; Li JH; Chen HF; Tan YY; Liu SR; Zhang Y; Xu H; Yang JH; Liu S; Zheng LL; Huang MB; Guo YH; Zhang Q; Zhou H; Qu LH
Cell Death Differ; 2018 Sep; 25(9):1581-1597. PubMed ID: 29449644
[TBL] [Abstract][Full Text] [Related]
31. Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer
Liermann J; Naumann P; Fortunato F; Schmid TE; Weber KJ; Debus J; Combs SE
Radiol Oncol; 2017 Dec; 51(4):407-414. PubMed ID: 29333119
[TBL] [Abstract][Full Text] [Related]
32. Crosstalk between p38 MAPK and caspase-9 regulates mitochondria-mediated apoptosis induced by tetra-α-(4-carboxyphenoxy) phthalocyanine zinc photodynamic therapy in LoVo cells.
Wang Y; Xia C; Lun Z; Lv Y; Chen W; Li T
Oncol Rep; 2018 Jan; 39(1):61-70. PubMed ID: 29115534
[TBL] [Abstract][Full Text] [Related]
33. Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine.
Zhang Y; Liang Y; He C
Chin Med; 2017; 12():20. PubMed ID: 28702078
[TBL] [Abstract][Full Text] [Related]
34. Neurogenic Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer's Disease.
Sreenivasmurthy SG; Liu JY; Song JX; Yang CB; Malampati S; Wang ZY; Huang YY; Li M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134846
[TBL] [Abstract][Full Text] [Related]
35. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.
Lu XS; Qiao YB; Li Y; Yang B; Chen MB; Xing CG
Oncotarget; 2017 Jan; 8(1):988-998. PubMed ID: 27894091
[TBL] [Abstract][Full Text] [Related]
36. The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Dong YY; Zhuang YH; Cai WJ; Liu Y; Zou WB
Tumour Biol; 2016 Nov; 37(11):15053-15063. PubMed ID: 27658776
[TBL] [Abstract][Full Text] [Related]
37. Molecular Insight in the Multifunctional Effects of Oridonin.
Owona BA; Schluesener HJ
Drugs R D; 2015 Sep; 15(3):233-44. PubMed ID: 26290464
[TBL] [Abstract][Full Text] [Related]
38. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
Chen B; Xu M; Zhang H; Xu MZ; Wang XJ; Tang QH; Tang JY
DNA Cell Biol; 2015 Oct; 34(10):610-7. PubMed ID: 26284306
[TBL] [Abstract][Full Text] [Related]
39. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
[TBL] [Abstract][Full Text] [Related]
40. Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells.
Gui Z; Li S; Liu X; Xu B; Xu J
BMC Complement Altern Med; 2015 Apr; 15():117. PubMed ID: 25880988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
